圖表

簡介

病因

危險因素和預防

疾病診斷

變異：各地區/民族

疾病預後和臨床過程

疾病相關的主要併發症/特徵

定量化患者數的手法

追加資料

主動脈瓣狹窄症的盛行率top line

主動脈瓣狹窄症患者的特徵

主動脈瓣狹窄症的重病度

主動脈瓣狹窄症的原因論

主動脈瓣狹窄症的NYHA分類 (心機能力分類)

輕度

重度

重度主動脈瓣狹窄症的症候性 vs. 無症狀性

重度症候性主動脈瓣狹窄症相關的併發症

簡稱

相關出版

患者為基礎的線上資料庫

患者為基礎的產品

價格的線上資料、平台

參考文件

附錄

目錄

Product Code: AOST0011115

Aortic Stenosis (AS) is the occlusion or loss of aortic valve surface area resulting in stenosis of the aortic valve. Currently, AS is thought to be the most common form of valvular heart disease in Western countries. This report provides the current prevalent population for AS across 16 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Turkey, Mexico, Canada, Australia, Finland, Poland, Argentina and China) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the risk factors, aetiology, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AS have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Aortic Stenosis include:

Previous myocardial infarct / Angina

Carotid atherosclerosis

COPD

Lower limb atherosclerosis

Atrial fibrillation

Heart failure

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global AS's market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of AS and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on AS's prevalent population.

Identify sub-populations within AS which require treatment.

Gain an understanding of the specific markets that have the largest number of AS patients.